Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Pimodivir in Renal Impairment
NCT03947814Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pimodivir in Influenza A (IAV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Concentration, Area Under Curve From Time of Dosing to the Time of the last Measurable Concentration and 1 more. Started Jul 2019; status: terminated.
02
Drugs
pimodivir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03947814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947814.